Base business solid, semaglutide stumble masks underlying strength

ex-Lenalidomide growth masked by -5.6% overall revenue; North America ex-Lena +19% QoQ but -41% YoY

Reported 12.5%; ₹240 Cr provision is material but one-time; adjusted margin = 15.4% confirmed

Delivered 17% YoY and 10% QoQ; organic (ex-acquisitions) 15.5% per MVN

Reported ₹1,833 Cr +31% YoY; outperformance vs. India pharma market growth of 11-14%

Sold 180K pens before stoppage; targeting 6-7M Nov-Mar (down from 10-11M plan), implies ~4M opportunity cost

4-month production gap cost opportunity; sold 180K pens Q1, now targeting 6-7M Nov-Mar vs. prior full-year multi-million plan. Competitors (Apotex) entering market.

Pre-License Inspection June 2026 issued Form 483 with 7 vs. prior 5 observations. Management claims addressable; 80-90% confidence on Dec approval, but risk remains.

Declined 1,039 bps YoY (lenalidomide, solvent/freight via Middle East conflict ~1% of EBITDA, semaglutide provision). Adjusted (ex-provision) 49.4%.

Delivered 17% reported (10% QoQ), organic 15.5% ex-acquisitions. Within guided 15%+ but lower end; volume + price + innovation driving.

High-teens now ~18%, maintained 20% neighborhood for full year. Semaglutide resumption Nov will lift margins above 20%. Emerging Markets growth 15%+ and cost leverage will drive productivity.

7 observations very different, addressable, submitted response Friday (within timeline). No BLA queries as of call date. Goal date December still intact. Two risk types: additional GMP queries (addressable) or BLA queries (could delay). Confident on approval.

SG&A growth 75-80% from adverse forex + Middle East freight. Otherwise low growth. Emerging Markets growth 15%+ while cost growth low single-digit = 10-12% productivity gap to materialize.

180K sold before stop. Capacity 300+ (theoretical 550 with expansion); plenty for both captive and 3P. Quality, not capacity, the issue now. Expected 6-7M pens Nov-Mar (3-4M opportunity loss).

Demand for 6-7M backed with orders. Spec sheets stay same, file good, drug product quality good. No delays anticipated anywhere, including Brazil. ~30 countries already filed for 80-country program.

Root cause identified, remediation activities underway by Sept 22-23. Success rate 80-90%; not 100% but feeling confident. Fingers crossed.

Price erosion single/double-digit through period. US market structural low-single-digit growth. New products compensate for erosion. ROI seen in Emerging Markets/Europe leveraging US portfolio, not US direct. Productivity issues acknowledged (iron sucrose, conjugated estrogen, peptides late).

Never planned CMO (was considered for tariff hedge but tariff risk became non-relevant). CMO post-approval only. Launch from Bachupally. Goal December 2026; two risks: GMP queries (addressable), BLA queries (possible, could delay).

Organic 15.5% ex-acquisitions. Semaglutide supply not much contributor in India. Driven by innovation, new launches, price, volume.

Rituximab will be interchangeable. Same USFDA PLI inspection covered both abatacept and rituximab. Once we get approval, interchangeability confirmed.

Price CAD 78 (Day 1 reflected 3-player scenario). Margins 38% retail + 5-6% provincial rebate. No additional pricing anticipated. One competitor using our API; another waiting for us to resolve issues.

Confidence high. 6-7M backed by orders. Not just Canada; approval expected in multiple markets. Partner engagement strong. Apotex will be sole competitor in some markets; only 2 of us expected.

Trend is growth. Q1 decline due to inventory cutoff in some markets + Brazil tender timing (won but not fulfilled Q1). Healthy margin expected to continue.

Brazil approval shortly; rejection reversal completed. Expect approval next few weeks. Interchangeability: no problems; product approved as generic. Synth vs. recombinant API doesn't affect interchangeability; comparability + safety data suffices.

Emerging Markets +31% YoY, India organic +15.5%, North America base double-digit, Europe 24 launches; management reiterated multiple times.

6 launched Q1 (bosutinib, nintedanib, etc.); 27 total for year. Q2 launch timing firm; revenue scale tens-of-millions $, not named.

Backed by partner orders. Contingent on API fix Sept 22-23 (80-90% success). 4-month gap opportunity cost ~3-4M pens vs. plan.

Adjusted Q1 ~18%, high-teens (ex-semaglutide provision + other one-times). FY26 guidance 50-55% gross margin starting Q4; delayed by semaglutide/logistics headwinds.

Both solvent + freight ≈1% EBITDA hit. War escalation signals no recovery until year-end per CFO.

Q1 benefited from tax provision reversals (favorable earlier-year assessment resolution). FY27 expect 24-25%.

Reflects completion of biologics (Bachupally CCM-5, FFM-2 for abatacept) and peptides capacities. Ongoing investments in biosimilars, peptides R&D.

API production fix only 80-90% probable by late September; failure delays November resumption, costs 3-4M pen sales FY27, erodes 6-7M recovery target. Material impact on FY27 semaglutide contribution and full-year revenue forecast.

Pre-License Inspection returned 7 Form 483 observations (vs. prior 5); 2 risk types: additional GMP queries (addressable but possible) or BLA queries (could delay). December 2026 goal date intact but FY28 revenue contribution now exposed if approval slips post-Dec or queries require manufacturing rework.

Gross margin fell 1,039 bps YoY (46.5% vs. ~55%); drivers: Lenalidomide phase-out, Middle East solvent/freight cost spike (~1% EBITDA), semaglutide provision ₹240 Cr. Even adjusted 49.4% (ex-provision) still down 500+ bps. Normalized 50-55% margin reset target now delayed indefinitely; FY27 consensus expecting 48-50% range. Risk: if semaglutide recovery falters or ME crisis persists, margin floor tested.

US generic market structural low-single-digit growth with ongoing price erosion (single/double-digit annually). DRL launched 90-100 products over 4 years + Mayne acquisition (US$100M), yet revenue flat at US$950M run-rate (FY22 ≈ US$1,000M). Implies 100+ product launches did not offset erosion. North America -41% YoY (Lena impact), +19% QoQ base (timing noise). Long-term risk: unless R&D productivity and complex generics (injectables, respiratory) improve materially, US segment growth will remain low-single-digit.

Abatacept launch expected (if approved Dec 2026) from single site (Bachupally); no CMO backup. If Bachupally faces inspection findings or scale-up issues post-launch, no alternate supply source. Biologics breakeven implied on abatacept launch day per CEO; if launch delayed or supply-constrained, profitability delayed. IV form Dec target, subcutaneous (larger market) FY28.